- Home
- MYND vs IGC Comparison
MYND vs IGC Comparison
Compare MYND & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYND
- IGC
- Stock Information
- Founded
- MYND 1998
- IGC 2005
- Country
- MYND United States
- IGC United States
- Employees
- MYND N/A
- IGC N/A
- Industry
- MYND Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MYND Real Estate
- IGC Health Care
- Exchange
- MYND Nasdaq
- IGC Nasdaq
- Market Cap
- MYND 37.0M
- IGC 39.8M
- IPO Year
- MYND 2017
- IGC N/A
- Fundamental
- Price
- MYND $0.67
- IGC $0.39
- Analyst Decision
- MYND
- IGC Strong Buy
- Analyst Count
- MYND 0
- IGC 2
- Target Price
- MYND N/A
- IGC $4.00
- AVG Volume (30 Days)
- MYND 23.3K
- IGC 968.4K
- Earning Date
- MYND 08-27-2025
- IGC 11-14-2025
- Dividend Yield
- MYND N/A
- IGC N/A
- EPS Growth
- MYND N/A
- IGC N/A
- EPS
- MYND N/A
- IGC N/A
- Revenue
- MYND $209,800,000.00
- IGC $1,327,000.00
- Revenue This Year
- MYND N/A
- IGC $3.54
- Revenue Next Year
- MYND N/A
- IGC $15.12
- P/E Ratio
- MYND N/A
- IGC N/A
- Revenue Growth
- MYND N/A
- IGC 24.95
- 52 Week Low
- MYND $0.53
- IGC $0.25
- 52 Week High
- MYND $3.89
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- MYND 41.38
- IGC 45.99
- Support Level
- MYND $0.64
- IGC $0.38
- Resistance Level
- MYND $0.72
- IGC $0.45
- Average True Range (ATR)
- MYND 0.05
- IGC 0.02
- MACD
- MYND -0.00
- IGC -0.00
- Stochastic Oscillator
- MYND 51.05
- IGC 35.52
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.